Lead Product(s): P014
Therapeutic Area: Immunology Product Name: P014
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Quan Capital
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 12, 2020
Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.